Abstract
Purpose: The NCCN currently recommends external beam radiotherapy (EBRT) ± brachytherapy (BT) boost ± androgen deprivation therapy (ADT) for men with unfavorable intermediate-risk prostate cancer (UIR-PCa). The role of brachytherapy ± ADT in the absence of EBRT is not well defined in UIR-PCa. Radiation Therapy Oncology Group (RTOG) 0232, which randomized favorable intermediate-risk patients to definitive BT versus EBRT+BT boost, reported no progression-free survival (PFS) benefit to adding EBRT to BT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
